Skip to main content
. 2021 Mar 5;22:186. doi: 10.1186/s13063-021-05075-1

Table 3.

Outcomes and timing of assessments

Study variable Instrument Outcome (range)
Maternal: measured at baseline and 3a-, 6-, and 12-month post-randomization
Maternal characteristicsb Trial Baseline Questionnaire [54, 55] Self-reported age, education level, gender and sexual orientation, marital status, race, immigrant status and ethnicity, clinical history with depression or anxiety (severity, chronicity, number of prior episodes, and age at first episode), occupational status, number of children, pregnancy intention, pregnancy history, delivery, and birth.
Depressive symptoms Edinburgh Postnatal Depression Scale (EPDS) [44] Mean continuous score of a 10-item scale (0–30)
Anxiety symptoms Generalized Anxiety Disorder Scale (GAD-7) [45] Mean continuous score of a 7-item scale (0–21)
Response and remission Patient Health Questionnaire-9 (PHQ-9) [56]

Response: PHQ < 10

Remission is defined as PHQ < 5

Perceived support Multidimensional Scale of Perceived Social Support [57] Mean continuous score of a 12-item scale (1–84)
Disability assessment World Health Organization Disability Assessment Schedule (WHODAS) [58] Mean continuous score of a 12-item scale (0–48)
Quality of life assessment EQ 5D-5 Level [59] Mean continuous score of a 5-item scale (1–25)
Trauma symptoms Abbreviated PTSD Checklist (PCL-6) [60] Mean continuous score of a 6-item scale (1–30)
Patient-reported activation Premium Abbreviated Activation Scale [41, 61] Mean continuous score of a 5-item scale (0–20)
Patient satisfactionc Client Satisfaction Questionnaire-8 (CSQ-8) [62] Mean continuous score of an 8-item scale (1–32(
Therapeutic alliancec Working Alliance Inventory-Short Revise (WAI-SR) [63] Mean continuous score of a 12-item scale (1–60)
Health service utilization Health Service Utilization Form Total score of a 16-item scale (0–32)
Treatment preferenceb Delivery of treatment and treatment provider preference Score of 0 or 1
COVID-19 exposure 1-item question on COVID-19 exposure Self-reported
Treatment: measured at every session during treatment, unless otherwise indicated
Dosage Treatment log [64] Frequency of sessions attended
Therapy qualityd Quality of Healthy Activity Program (Q-HAP) [51] Mean continuous score of treatment-specific BA skills (0–4) and general counseling skills (0–4)
Session depressive/anxiety Session-by-session EPDS [44] and GAD-7 [45] scores Mean continuous score of a 10-item scale (0–30) on EPDS and of a 7-item scale (0–21) on GAD-7
Homework adherence Treatment log [64] Mean continuous score of a 1-item question (0–2)
Adverse or serious AEs Anytime an adverse event (AE) or serious AE occurs Any event that represents a series threat to the safety of the mother or her child
Health service utilization Health Service Utilization Form [65] Total score of a 16-item scale (0–32)
List of medications List of medications Self-reported list of medications
COVID-19 exposure 1-item question on COVID-19 exposure Self-reported
Child: measured at 9 to 15 months post-child birth unless otherwise indicated
Birth weight and length Retrieved from hospital chart or self-reporte Assessed at birth
Breastfeeding Whether breastfeeding and if stopped age stopped [55]. Total number of months (0–12)
Psychosocial stimulation Home Observation Measurement Evaluation [66] Total score of a 45-item checklist
Mental development Bayley Mental Development Scales IV [67] Mean continuous score of cognitive, receptive, and expressive language development

aAssessment period will be extended to account for post-treatment outcomes when there are perinatal-related interruptions to treatment (e.g., giving birth, obstetrical complications, COVID-19)

bOnly at baseline

cMeasured at 3 months post-randomization only

dRandomly selected for supervision, rated by self, peers, expert supervisor

eSelf-report will be used when hospital charts are outside of the recruiting site